BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1608856)

  • 1. Therapeutic frontiers in Alzheimer's disease.
    Miller SW; Mahoney JM; Jann MW
    Pharmacotherapy; 1992; 12(3):217-31. PubMed ID: 1608856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological basis of drug therapy of Alzheimer's disease.
    Sharma A; Parikh V; Singh M
    Indian J Exp Biol; 1997 Nov; 35(11):1146-55. PubMed ID: 9567741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: cognitive and behavioral pharmacotherapy.
    Cummings JL; Mendez MF
    Conn Med; 1997 Sep; 61(9):543-52. PubMed ID: 9334509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
    Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F
    Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lines of therapeutics research in Alzheimer's disease.
    Shvaloff A; Neuman E; Guez D
    Psychopharmacol Bull; 1996; 32(3):343-52. PubMed ID: 8961777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternatives in the treatment of memory loss in patients with Alzheimer's disease.
    Volger BW
    Clin Pharm; 1991 Jun; 10(6):447-56. PubMed ID: 2065522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of dementia: lessons from SYST-EUR and PROGRESS.
    Hanon O; Forette F
    J Neurol Sci; 2004 Nov; 226(1-2):71-4. PubMed ID: 15537524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease. A critical review.
    Gottfries CG
    Compr Gerontol C; 1988 Dec; 2(1):47-62. PubMed ID: 3076510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease.
    Craig LA; Hong NS; McDonald RJ
    Neurosci Biobehav Rev; 2011 May; 35(6):1397-409. PubMed ID: 21392524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.